GlaxoSmithKline PLC (GSK)

1,534.60
+0.60(+0.04%)
  • Volume:
    5,988,245
  • Bid/Ask:
    1,502.00/1,542.00
  • Day's Range:
    1,526.60 - 1,541.20

GSK Overview

Prev. Close
1,534
Day's Range
1,526.6-1,541.2
Revenue
33.33B
Open
1,538.8
52 wk Range
1,190.8-1,604.4
EPS
0.85
Volume
5,988,245
Market Cap
76.85B
Dividend (Yield)
80.00
(5.19%)
Average Vol. (3m)
7,452,589
P/E Ratio
17.97
Beta
0.64
1-Year Change
10.07%
Shares Outstanding
5,007,979,212
Next Earnings Date
Feb 09, 2022
What is your sentiment on GlaxoSmithKline PLC?
or
Market is currently closed. Voting is open during market hours.

GlaxoSmithKline PLC Company Profile

Employees
94066

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyBuySellSellStrong Buy
SummaryStrong BuyStrong BuyNeutralNeutralStrong Buy
  • 1st malaria vaccine approved by WHO. hopefully good news for the stock. definitely good for the developing world!
    0
    • Been In GSK since February and wearing almost a 15% gain which i'm pretty chuffed about , not sure what you guys think about GSK going into the future but i'm pretty happy with these returns and am thinking about investing in a PRE IPO called SpectrumX which i have seen on the homepage of LSE and the Sunday times. SpectrumXare leaders in proprietary formulations of HOCL, so looks promising for the future of pharmaceuticals. Have not dabbled with Pre IPOS so wanted to see what you guys think?
      1
      • to the moon!
        0
        • when?!
          0
        • Already mooned now buy back at 1300
          0
      • Good old GSK. Never fails to disappoint.
        0
        • AMAZING....great news, good earnings...it comes +2% to -0.7%....I`m done, I`m out
          0
        • As i said before this company does not understand competitive performance - radical change needed - one off hitting earnings forecast does not mean anything
          0
      • setting my buys at 12.5
        0
        • GSK will invent the vaccine of immortality
          0
          • Will not deliver on results - never does actually - the plans are all nice on paper - but its all just a financial excercise - the forecasts especially on oncology but not only are not real
            0
            • glx is about to split of the consumer division .
              0
              • Stock's been on fire these past 2 days. What's the driver?
                0
                • Anticipation that the briefing on the proposed split on 25 June will suggest an unlocking of value. GSK is a lame duck in the Covid race and in many other aspects, so also hope that the breakup will trigger bids for the separate businesses.
                  0
              • Best drug company there is.
                2
                • shall go over 15 before 23 June
                  0
              • Pharma sector will benefit the most 2021-2022, just wait for quartely reports.
                0
                • Walmsley has to go. As a CEO she is a train crash - how can a leading player in pharma specialising in vaccines, not be the leading light in a pandemic, with its share price following the stellar performance of AZ. Elliot management can see the value of GSK improving at least 30% when Walmsley is shown the door
                  1
                  • As someone that know GSK very well i can tell you - you cannot be more right - she has no idea what she is doing
                    0
                • Which is the target in 1 year time? Now it is 1,37
                  0
                  • One thing i can tell you - if they remove Emma then thjs will fly - before thst happens this is dead - she has no idea of how to run a competitive business - dreadful performance - IPT
                    0
                    • Bullish consolidation. Next move coming.
                      0
                      • I'm waiting the next results (Next week). What do you think what will happen with the price? the company results will be good or not? Thanks!
                        0
                        • Haven't been bad in the past, reliable business. At least they have earnings compared to many stonks.
                          0
                      • When can we sell?
                        0
                        • 1650p
                          0
                        • Thanks
                          0
                      • Told you so. More buyers than sellers.
                        0
                        • So that's why it rises
                          0
                          • BRIEF-Hedge Fund Elliott Builds Up Multi-billion-pound Stake In UK's GSK - Ft
                            0
                            • TO THE MOON!
                              1
                              • It dropped quickly from 15 to 12. Now only 13.5. The rise for one day doesn't mean much
                                0
                              • PE is 11 still cheap.
                                0
                              • It dropped quickly from 15 to 12. Now only 13.5. The rise for one day doesn't mean much
                                0
                            • I bought at 12.15 on 4th March. Looking forward after all this time waiting!
                              0
                              • going to 20
                                1
                                • 20 what?
                                  0
                                • not going to 20 anytime soon unfortunately, years away
                                  0
                              • nice, going to moon now, too late for those who didnt buy under 13
                                0
                                • It's a bargain atm. Big solid company, great div and plays as a safe haven. Price is far below average consensus, so there is a room to raise.
                                  0
                                  • Don't count on the dividend because they will cut it soon
                                    1
                                  • Who says?
                                    0
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.